Our findings in the drug-switching population also carry practical implications, suggesting a consideration for transitioning from etanercept to anti-TNFα monoclonal antibodies as a potential treatment strategy for recurrent anterior uveitis in patients with AS. This evidence concerns the gene TNF and anterior uveitis.